Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Loss of Mesothelin Expression by Mesothelioma Cells Grown In Vitro Determines Sensitivity to Anti-Mesothelin Immunotoxin SS1P

JINGLI ZHANG, SHUO QIU, YUJIAN ZHANG, MARIA MERINO, PATRICIA FETSCH, ITZHAK AVITAL, ARMANDO FILIE, IRA PASTAN and RAFFIT HASSAN
Anticancer Research December 2012, 32 (12) 5151-5158;
JINGLI ZHANG
1Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHUO QIU
1Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUJIAN ZHANG
1Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA MERINO
2Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PATRICIA FETSCH
2Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ITZHAK AVITAL
3Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ARMANDO FILIE
2Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IRA PASTAN
1Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RAFFIT HASSAN
1Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hassanr{at}mail.nih.gov
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Characterization of patients' tissue biopsy and early-passage mesothelioma cells. H&E staining of the patients' original tissue biopsy (A) and mesothelin staining of original tissue biopsy using the anti-mesothelin mAb 5B2 (B). Morphological features of the sections made from the cell blocks of patient tumor cells grown in short-term culture (C) as well as mesothelin staining using the anti-mesothelin mAb 5B2 (D).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    FACS analysis for mesothelin expression of patients' tumor cells grown in short-term culture. Cells were incubated with the anti-mesothelin mAb MN, conjugated with R-PE or isotype control antibody. Results are shown in terms of histogram plots for each cell line where the shaded area depicts the binding of MN antibody and the clear area shows the binding of isotype control antibody. The number of mesothelin sites/cell for each of the early-passage mesothelioma cell cultures is shown in each histograph.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Cytotoxicity of SS1P against early-passage mesothelioma cells. (A) NCI-M-02 cells (5×104) were seeded in a 24 well plate and treated with 10 ng/ml of SS1P or BL22. After 96 h of incubation the cells were washed, fixed and cell viability was assessed by the crystal violet assay. (B) Effect of SS1P (10 ng/ml) on the different early-passage mesothelioma cells using the crystal violet assay. The y-axis represents percent cell death as compared to control untreated cells. Data represents the mean±SD of triplicate samples. (C) Spearman correlation analysis was performed using Graphpad to show the correlation between SS1P cytotoxicity and mesothelin sites/cell expressed by the early-passage mesothelioma cells.

Tables

  • Figures
  • Table I.
  • Table II.
  • Table III.
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 32, Issue 12
December 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Loss of Mesothelin Expression by Mesothelioma Cells Grown In Vitro Determines Sensitivity to Anti-Mesothelin Immunotoxin SS1P
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
16 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Loss of Mesothelin Expression by Mesothelioma Cells Grown In Vitro Determines Sensitivity to Anti-Mesothelin Immunotoxin SS1P
JINGLI ZHANG, SHUO QIU, YUJIAN ZHANG, MARIA MERINO, PATRICIA FETSCH, ITZHAK AVITAL, ARMANDO FILIE, IRA PASTAN, RAFFIT HASSAN
Anticancer Research Dec 2012, 32 (12) 5151-5158;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Loss of Mesothelin Expression by Mesothelioma Cells Grown In Vitro Determines Sensitivity to Anti-Mesothelin Immunotoxin SS1P
JINGLI ZHANG, SHUO QIU, YUJIAN ZHANG, MARIA MERINO, PATRICIA FETSCH, ITZHAK AVITAL, ARMANDO FILIE, IRA PASTAN, RAFFIT HASSAN
Anticancer Research Dec 2012, 32 (12) 5151-5158;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Material and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Rapid CAR screening and circRNA-driven CAR-NK cells for persistent shed-resistant immunotherapy
  • Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
  • Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors
  • Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers
  • An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
  • Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
  • Google Scholar

More in this TOC Section

  • Low-dose Andrographolide Synergizes With Cytarabine or Vincristine in Plasma Cell Neoplasm Cell Lines
  • Enzalutamide Enhanced Honokiol-induced Apoptotic Insults to Drug-resistant Glioblastoma Cells via an Intrinsic Bak-mitochondrion-caspase Cascade Mechanism
  • Milk Extracellular Vesicle–mediated Delivery of siPRNP Suppresses Growth and Wound Closure in PC-3M Prostate Cancer Cells
Show more Experimental Studies

Keywords

  • Mesothelin
  • MPF
  • SS1P
  • pleural mesothelioma
  • peritoneal mesothelioma
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire